A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study
- 31 May 2011
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 47 (7), 1037-1045
- https://doi.org/10.1016/j.ejca.2011.01.001
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Third consensus on medical treatment of metastatic breast cancerAnnals Of Oncology, 2009
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent ChemotherapyJNCI Journal of the National Cancer Institute, 2009
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patientsAnnals of Oncology, 2008
- Impact of chemotherapy beyond the first line in patients with metastatic breast cancerBreast Cancer Research and Treatment, 2007
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- Preclinical Evaluation of New TaxoidsCurrent Pharmaceutical Design, 2001
- Factors determining cellular mechanisms of resistance to antimitotic drugsDrug Resistance Updates, 2001
- A unified definition of clinical anthracycline resistance breast cancerBritish Journal of Cancer, 2000
- Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell DeathJournal of Clinical Oncology, 1999
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999